Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | OGA | O60502 | 12/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MANBA | O00462 | 1/20 | 0.40 |
| ▸ | PYGB | P11216 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17978030 | 1.00 | GBA1 (0.50) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL4207953 | 0.77 | GBA1 (0.55) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL9297697 | 0.77 | GBA1 (0.55) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL321985 | 0.77 | GBA1 (0.55) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL7826551 | 0.73 | OGA (0.42) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL1521522 | 0.72 | OGA (0.44) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL5666013 | 0.72 | OGA (0.44) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL1521106 | 0.72 | OGA (0.44) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL5666062 | 0.71 | GBA1 (0.47) | GBA1LMNAOGAGAAMANBA | |
| SCHEMBL8495531 | 0.71 | GBA1 (0.47) | GBA1LMNAOGAGAAMANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272953-A1 | Activated Sugars | THE PROCTER & GAMBLE COMPANY | 2016-09-22 | — | — | US | disclosed |
| US-20140024082-A1 | Activated Sugars | ZUCHEM INC | 2014-01-23 | — | — | US | disclosed |
| US-8618269-B2 | Glycorandomization and production of novel novobiocin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2606141-A2 | ACTIVATED SUGARS | Zuchem, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024678-A9 | ACTIVATED SUGARS | ZUCHEM, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2012024678-A2 | ACTIVATED SUGARS | ZUCHEM, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-20050266523-A1 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-12-01 | — | — | US | disclosed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040259228-A1 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-23 | — | — | US | disclosed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | disclosed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | GBA1 420/4885LMNA 3563/4885OGA 64/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | GBA1 160/4885LMNA 2801/4885OGA 90/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | GBA1 421/4885LMNA 3817/4885OGA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.